Latest Industry Insights
Thinking Differently: The Potential of Psilocybin Therapy To Transform the Mental Healthcare Landscape
Poor mental health is a growing burden on global healthcare systems. In this opinion piece, Compass Pathways chief medical officer Professor Guy Goodwin reviews currently available treatments options and the results from his company's new clinical trial into the efficacy of the psychedelic psilocybin in treating mental health conditions.
Developing a Vaccine for Alzheimer’s Disease
To learn more about a universal vaccine technology and how the platform could be applied to Alzheimer's disease and other neurological indications, Technology Networks spoke with Roman Kniazev, chief executive officer at Nuravax.
“I’ve Never Seen Anything as Effective”: Exploring the Combination of Psychedelics and Psychotherapy
While most psychedelic drugs remain illegal in the United States, ketamine has been legal for use by registered practitioners since the 1960s. With the recent recognition of the compound’s use as an antidepressant, more and more clinics are rolling out ketamine-assisted psychotherapy programs.
Can Psilocybin Help Smokers Quit? This Clinical Trial Aims to Find Out
Psilocybin – the primary active ingredient in magic mushrooms – is to be studied in a new clinical trial that will test whether the psychedelic compound can help people quit smoking.
Early Detection of Brain Tumors and Beyond
The ability to detect a tumor earlier, when it is smaller, reduces the impact of surgery and treatment, improving the prognosis for many patients. Dxcover has developed a new spectroscopic liquid biopsy approach that is able to identify brain tumors as small as 0.2 cm3 from a blood sample in as little as fifteen minutes.
MDMA for Traumatic Brain Injury To Be Studied in $1.5 Million Partnership
A new partnership between MAPS Public Benefit Corp (PBC) and Wesana Health will see $1.5 million contributed towards investigation into the therapeutic potential of the psychedelic compound MDMA in treating traumatic brain injury (TBI).
How Can AI Techniques Improve How We Diagnose Dementia?
Developing treatments for dementia remains one of the most forbidding challenges facing neurology. Traditionally, paper-based assessments are used by clinicians to diagnose patients. But London-based company Cognetivity says that its AI-based platform could improve diagnostics. We spoke with the company’s co-founder and chief science officer, Dr. Seyed Khaligh-Razavi, to find out more.
How Can We Make It Easier To Implant a Brain-Computer Interface?
Brain-computer interfaces (BCI) have the potential to revolutionize the lives of people with severe motor and nervous system impairments. But users of current BCI technology must face the hurdle of implanting the device in their brain. We spoke to Professor Florian Solzbacher, co-founder and chairman of Blackrock, to find out more about how neurotechnology companies are overcoming this obstacle.
Accelerating Biological Discovery With Open-Source Spatial Genomics Data
In this interview, Dr. George Emanuel discusses some of the most exciting findings from the Mouse Receptor Map and highlights how the datasets will benefit the Human Cell Atlas project.